Abstract: Objective To evaluate the efficacy and safety of stereotactic body radiotherapy for patients with oligometastatic tumor. Methods Eighty-five patients with 1-5 metastatic sites， life expectancy＞3 months， and also good performance status， which hospitalized from June 2011 to December 2016 were enrolled， SBRT therapy were performed for those patients， during this process， escalated doses of SBRT to all known metastatic sites. The primary end points were local control rate and toxicity. Secondary end points were overall survival（OS） and progression-free survival（PFS）. Tumor response and Local control were defined using EORTC-RECIST Criteria v. 1.1. Acute and late toxicity were scored by the RTOG evaluation criterion. The survial rates were calculated by Kaplan-Meier analysis. The differences among the modalities were evaluated using the Log-rank test. Results A total of 85 patients， 187 metastastic sites complete the treatment，the median follow-up of 25 months， local control rate of the whole team was 66.8％， local control rate of the three treatment modalities 24， 30， 36Gy were 39.0％， 79.0％， 84％， respetively， showing a significant difference between the groups（P＜0.05）.The medium time of PFS was 7.8 months. The 1-， 2-， 3-year progression-free survival rate was 33.3％, 25.0％, 23.0％. The medium overall survival time was 25 months. The 1-， 2-， 3-year survival rate was 80.5％，75.6％，70.6％. Four patients had acute toxic reactions over grade 3, including 2 patients with pulmonary metastasis proved to be radioactive pneumonia 2 months later, and one patient with liver metastases occurred severe vomiting and elevated transaminase, and one patient with liver, lung and bone metastasis occurred grade 4 bone marrow suppression.Conclusion Patients with oligometastatic disease can be identified， in a safe treatment scope， SBRT can achieve good local control rate， with tolerable adverse effects.